astragaloside a has been researched along with Cardiomyopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, L; Li, H; Li, Z; Lin, J; Lyu, L; Wang, H; Xiao, J | 1 |
| Chen, JB; Li, L; Tao, HY | 1 |
2 other study(ies) available for astragaloside a and Cardiomyopathies
| Article | Year |
|---|---|
Astragaloside IV alleviates doxorubicin induced cardiomyopathy by inhibiting NADPH oxidase derived oxidative stress.
Topics: Animals; Body Weight; Cardiomyopathies; Cardiotoxicity; Cell Size; Doxorubicin; Gene Expression Regulation; Male; Mice; Myocytes, Cardiac; NADPH Oxidase 2; NADPH Oxidase 4; Organ Size; Oxidative Stress; Rats; Saponins; Triterpenes | 2019 |
[Anti-apoptosis effect of astragaloside on adriamycin induced rat's cardiotoxicity].
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cardiomyopathies; Doxorubicin; Female; Immunohistochemistry; In Situ Nick-End Labeling; Male; Myocytes, Cardiac; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Saponins; Triterpenes | 2006 |